High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: A cross-sectional study

BMC Pediatrics

Volumn 12, Issue , 2012, Pages

  Innes, Steve ^a   Cotton, Mark F ^a   Haubrich, Richard ^b   Conradie, Maria M ^c   van Niekerk, Margaret ^c   Edson, Clair ^c   Rabie, Helena ^c   Jain, Sonia ^b   Sun, Xiaoying ^b   Zöllner, Ekkehard W ^c   Hough, Stephen ^c   Browne, Sara H ^d  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE;

ANTHROPOMETRY; ARTICLE; BICEPS BRACHII MUSCLE; BODY COMPOSITION; BODY FAT; CHILD; CONSENSUS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET THERAPY; DIETITIAN; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMB; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT; PEDIATRICIAN; PREPUBERTY; PRESCHOOL CHILD; PREVALENCE; RATING SCALE; RISK FACTOR; SCHOOL CHILD; SKINFOLD THICKNESS; SOUTH AFRICA; TREATMENT DURATION; TRICEPS BRACHII MUSCLE; TRUNK;

ABSORPTIOMETRY, PHOTON; ADIPOSITY; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; PREVALENCE; RISK FACTORS; SOUTH AFRICA; STAVUDINE; TIME FACTORS;

EID: 84869885561     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-12-183     Document Type: Article

References (27)

1. Reynolds NR, Neidig JL, Wu AW, Gifford AL, Holmes WC. Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution. AIDS Care 2006, 18(7):663-673. 10.1080/09540120500287051, 16971273.
2. Greeff M, Phetlhu R, Makoae LN, Dlamini PS, Holzemer WL, Naidoo JR, Kohi TW, Uys LR, Chirwa ML. Disclosure of HIV status: experiences and perceptions of persons living with HIV/AIDS and nurses involved in their care in Africa. Qual Health Res 2008, 18(3):311-324. 10.1177/1049732307311118, 18235155.
3. Nyblade L, Pande R, Mathur S, MacQuarrie K, Kidd R, Banteyerga H, Kidanu A, Kilonzo G, Mbwambo J, Bond V. Disentangling HIV and AIDS stigma in Ethiopia, Tanzania and Zambia 2003, Washington DC: International Center for Research on Women.
4. Stankov MV, Lucke T, Das AM, Schmidt RE, Behrens GM. Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors. Antimicrob Agents Chemother 2010, 54(1):280-287. 10.1128/AAC.00914-09, 2798495, 19805555.
5. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C, . the APROCO study group Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001, 15(18):2441-2444. 10.1097/00002030-200112070-00012, 11740195, the APROCO study group.
6. WHO, UNAIDS, UNICEF Global HIV/AIDS Response Progress Report 2011 http://www.who.int/hiv/pub/progress_report2011/hiv_full_report_2011.pdf, WHO, UNAIDS, UNICEF.
7. Statistics South Africa: Mid-year population estimates 2009, http://www.statssa.gov.za/publications/statsdownload.asp?PPN=p0302&SCH=4437.
8. Eley B. Metabolic complications of antiretroviral therapy in HIV-infected children. Expert Opin Drug Metab Toxicol 2008, 4(1):37-49. 10.1517/17425255.4.1.37, 18370857.
9. Hartman K, Verweel G, de Groot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006, 25(5):427-431. 10.1097/01.inf.0000215003.32256.aa, 16645507.
10. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003, 361(9359):726-735. 10.1016/S0140-6736(03)12656-6, 12620736.
11. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther 2007, 12(8):1247-1254.
12. Madhi SA, Adrian P, Cotton MF, McIntyre JA, Jean-Philippe P, Meadows S, Nachman S, Kayhty H, Klugman KP, Violari A. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010 Aug 15, 202(3):355-361.
13. Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggini V, Lepri AC, Mologni D, Mazzotta F, D'Arminio Monforte A, Mussini C, Cossarizza A, Galli M, . for the Icona Foundation Study Group Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008, 22(14):1769-1778. 10.1097/QAD.0b013e32830b3a96, 18753860, for the Icona Foundation Study Group.
14. Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N, Houang M, Chevenne D, Hankard R, Bresson JL, Blanche S, Levy-Marchal C. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005, 40(2):161-168. 10.1097/01.qai.0000178930.93033.f2, 16186733.
15. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007, 166(1):13-21.
16. Dzwonek AB, Lawson MS, Cole TJ, Novelli V. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 43(1):121-123. 10.1097/01.qai.0000230523.94588.85, 16936560.
17. Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A, Thorne C, . for the European Paediatric HIV and Lipodystrophy Study Group Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr 2012, 59(3):314-324. 10.1097/QAI.0b013e31824330cb, 3433033, 22205436, for the European Paediatric HIV and Lipodystrophy Study Group.
18. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J, Borum P, Meyer WA, Hardin DS, Mulligan K, . for the Pediatric AIDS Clinical Trials Group P1045 team Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009, 23:661-672. 2680185, 19279441, for the Pediatric AIDS Clinical Trials Group P1045 team.
19. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV, . AIDS Clinical Trials Group (ACTG) A5142 Study Team Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009, 23(9):1109-1118. 10.1097/QAD.0b013e32832b4377, 2739977, 19417580, AIDS Clinical Trials Group (ACTG) A5142 Study Team.
20. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, Milinkovic A, Gatell J, Ribera E. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007, 8(5):679-688. 10.1517/14656566.8.5.679, 17376022.
21. McComsey GA, Lo Re V, O'Riordan M, Walker UA, Lebrecht D, Baron E, Mounzer K, Frank I. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 2008, 46(8):1290-1296. 10.1086/529384, 2430521, 18444869.
22. Milinkovic A, Martinez E, Lopez S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007, 12(3):407-415.
23. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005, 6(4):197-202. 10.1310/ED57-EU48-RK6A-E5U0, 16214736.
24. Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici MF, Schultze ME, Woods L, Loewen DF, Kaul S, Cross A, Rutkiewicz VL, Rosenblatt HM, Hanson IC, Shearer WT. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995, 96:247-252.
25. Kaul S, Kline MW, Church JA, Dunkle LM. Determination of dosing guidelines for stavudine (2′,3′-didehydro-3′-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 2001, 45(3):758-763. 10.1128/AAC.45.3.758-763.2001, 90369, 11181356.
26. World Health Organization Addendum To 2006 Who Guidelines On Antiretroviral Therapy For Hiv Infection In Adults And Adolescents 2007, http://www.who.int/hiv/art/ARTadultsaddendum.pdf, World Health Organization.
27. Innes S, Levin L, Cotton MF. Lipodystrophy syndrome in HIV-infected children on HAART. S Afr J HIV Med 2009, 10(4):76-80. (NIHMS218910) (PMCID2919754).